Skip to Content

Riding the Ozempic wave


Rabid demand for weight-loss drugs like Ozempic and Wegovy is altering U.S. society and transforming the healthcare industry. Rapid Response host Bob Safian guides us through the upheaval and lessons, talking with CEO Zach Reitano of Ro, a telehealth platform that has ridden the wave to a $7 billion valuation. Reitano shares why he chose obesity-treatment as his company’s “hero product,” the impact of weight-loss drugs on industries beyond health-care, and why the potential of GLP-1s like Ozempic mirrors that of AI.


“Progress can emerge in unexpected ways and in unexpected areas.”